Srirangalingam U, LeCain M, Tufton N, Akker S A, Drake W M, Metcalfe K
Department of Endocrinology, St. Bartholomew's Hospital, Queen Mary University of London, West Smithfield, London, EC1A 7BE, UK.
Fam Cancer. 2017 Apr;16(2):279-282. doi: 10.1007/s10689-016-9946-9.
SDHB mutations are linked to the familial paraganglioma syndrome type 4 (PGL4), which is associated with predominantly extra-adrenal disease and has high metastatic rates. Despite the lower penetrance rates in carriers of SDHB mutations compared to mutations in other paraganglioma susceptibility genes, the aggressive behavior of SDHB-linked disease warrants intensive surveillance to identify and resect tumors early. Patients with similar SDHB genotypes in whom the PGL syndrome manifests often exhibit very heterogeneous phenotypes. Tumors can arise in various locations, and management can be considerably different, depending on tumor site and pathology. We present a case series of five SDHB mutation carriers over four generations from the same family to illustrate the complexities in management.
SDHB突变与4型家族性副神经节瘤综合征(PGL4)相关,该综合征主要与肾上腺外疾病相关且转移率高。尽管与其他副神经节瘤易感基因突变相比,SDHB突变携带者的外显率较低,但SDHB相关疾病的侵袭性特征仍需要进行密切监测以便早期识别和切除肿瘤。携带相似SDHB基因型且表现出PGL综合征的患者通常具有非常异质性的表型。肿瘤可发生于不同部位,其治疗方法会因肿瘤部位和病理情况而有很大差异。我们展示了来自同一家族四代的五名SDHB突变携带者的病例系列,以说明治疗中的复杂性。